Modest abuse-related subjective effects of zolpidem in drug-naive volunteers

Behavioural Pharmacology

Volumn 22, Issue 2, 2011, Pages 160-166

  Licata, Stephanie C ^a   Mashhoon, Yasmin ^a   MacLean, Robert R ^a   Lukas, Scott E ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

abuse; benzodiazepine; choice; human volunteer; hypnotic; self report; subjective effects; zolpidem

Indexed keywords

PLACEBO; ZOLPIDEM; ZOLPIDEM TARTRATE;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; QUESTIONNAIRE; SEDATION;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PYRIDINES; QUESTIONNAIRES; REINFORCEMENT (PSYCHOLOGY); SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 79952994172     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328343d78a     Document Type: Article

References (47)

1. Abe K (2008). Zolpidem therapy for movement disorders. Recent Pat CNS Drug Discov 3:55-60. (Pubitemid 351223185)
2. Bailey JE, Papadopoulos A, Seddon K, Nutt DJ (2009). A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety. J Psychopharmacol 23:117-122.
3. Balkin TJ, O'Donnell VM, Wesensten N, McCann U, Belenky G (1992). Comparison of the daytime sleep and performance effects of zolpidem versus triazoalm. Psychopharmacology 107:83-88.
4. Benavides J, Peny B, Dubois A, Perrault G, Morel E, Zivkovic B, Scatton B (1988). In vivo interaction of zolpidem with central benzodiazepine (BZD) binding sites (as labeled by [3H]Ro 15-1788) in the mouse brain. Preferential affinity of zolpidem for the omega 1 (BZD1) subtype. J Pharmacol Exp Ther 245:1033-1041.
5. Bray S, Shimojo S, O'Doherty JP (2010). Human medial orbitofrontal cortex is recruited during experience of imagined and real rewards. J Neurophysiol 103:2506-2512.
6. Caldwell JA, Caldwell JL (2005). Fatigue in military aviation: an overview of US military-approved pharmacological countermeasures. Aviat Space Environ Med 76 (7 Suppl):C39-C51. (Pubitemid 40934331)
7. Correia CJ, Little C (2006). Use of a multiple-choice procedure with college student drinkers. Psychol Addict Behav 20:445-452. (Pubitemid 46006548)
8. Cubała WJ, Landowski J (2007). Seizure following sudden zolpidem withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 31:539-540. (Pubitemid 46209407)
9. De Wit H, Griffiths RR (1991). Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend 28:83-111.
10. Di Chiara G, Tanda G, Bassareo V, Pontieri F, Acquas E, Fenu S, et al. (1999). Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine. Ann N Y Acad Sci 877:461-485. (Pubitemid 29351873)
11. Evans SM, Funderburk FR, Griffiths RR (1990). Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 255:1246-1255.
12. Gilbert DL, Staats PS (1997). Seizure after withdrawal from supratherapeutic doses of zolpidem tartrate, a selective omega I benzodiazepine receptor agonist. J Pain Symptom Manage 14:118-120. (Pubitemid 27323500)
13. Griffiths RR, Weerts EM (1997). Benzodiazepine self-administration in humans and laboratory animals-implications for problems of long-term use and abuse. Psychopharmacology 134:1-37. (Pubitemid 27485546)
14. Griffiths RR, Troisi JR, Silverman K, Mumford GK (1993). Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 4:3-13. (Pubitemid 23062644)
15. Griffiths RR, Rush CR, Puhala KA (1996). Validation of the multiple-choice procedure for investigating drug reinforcement in humans. Exp Clin Psychopharmacol 4:97-106. (Pubitemid 26077300)
16. Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W (2003). Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98:1371-1378. (Pubitemid 37297243)
17. Huang MC, Lin HY, Chen CH (2007). Dependence on zolpidem. Psychiatry Clin Neurosci 61:207-208.
18. Jamieson AO, Zammit GK, Rosenberg RS, Davis JR, Walsh JK (2001). Zolpidem reduces the sleep disturbance of jet lag. Sleep Med 2:423-430. (Pubitemid 32952346)
19. Jasinski DR (1977). Assessment of the abuse potential of morphine-like drugs (methods used in man). In: Martin WR, editor. Drug addiction I. Vol. 45/1. Heidelberg: Springer-Verlag. pp. 197-258.
20. Karmacharya R, England ML, Ongür D (2008). Delirious mania: clinical features and treatment response. J Affect Disord 109:312-316.
21. Krueger TH, Kropp S, Huber TJ (2005). High-dose zolpidem dependence in a patient with chronic facial pain. Ann Pharmacother 39:773-774. (Pubitemid 40396643)
22. Lamb RJ, Preston KL, Schindler CW, Meisch RA, Davis F, Katz JL, et al. (1991). The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J Pharmacol Exp Ther 259:1165-1173.
23. Liappas IA, Malitas PN, Dimopoulos NP, Gitsa OE, Liappas AI, Nikolaou ChK, Christodoulou GN (2003). Zolpidem dependence case series: possible neurobiological mechanisms and clinical management. J Psychopharmacol 17:131-135. (Pubitemid 36373152)
24. Licata SC, Penetar DM, Dunlap S, Lukas SE (2008). A therapeutic dose of zolpidem has limited abuse-like effects in drug-näve females: a pilot study. Eur J Pharmacol 598:64-67.
25. Licata SC, Jensen JE, Penetar DM, Prescot AP, Lukas SE, Renshaw PF (2009). A therapeutic dose of zolpidem reduces thalamic GABA in healthy volunteers: a proton MRS study at 4T. Psychopharmacology 203:819-829.
26. Lile JA, Kelly TH, Hays LR (2010). The reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromor-phone, and methylphenidate in cannabis users. Behav Pharmacol 21:29-38.
27. McBeth BD, McNamara RM, Ankel FK, Mason EJ, Ling LJ, Flottemesch TJ, Asplin BR (2009). Modafinil and zolpidem use by emergency medicine residents. Acad Emerg Med 16:1311-1317.
28. Mumford GK, Evans SM, Fleishaker JC, Griffiths RR (1995). Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther 57:356-365.
29. 0-[5-(1- hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2 carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 327:969-981.
30. Petry NM, Bickel WK (1998). Polydrug abuse in heroin addicts: a behavioral economic analysis. Addiction 93:321-335. (Pubitemid 28120813)
31. Pick CG, Chernes Y, Rigai T, Rice KC, Schreiber S (2005). The antinociceptive effect of zolpidem and zopiclone in mice. Pharmacol Biochem Behav 81:417-423. (Pubitemid 40966786)
32. Rao S, Zisook S (2009). Anxious depression: clinical features and treatment. Curr Psychiatry Rep 11:429-436.
33. Roache JD, Griffiths RR (1989). Diazepam and triazolam self-administration in sedative abusers: concordance of subject ratings, performance and drug self-administration. Psychopharmacology 99:309-315. (Pubitemid 19244106)
34. Rowlett JK, Lelas S, Tornatzky W, Licata SC (2006). Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors. Psychopharmacology 184:201-211. (Pubitemid 43083657)
35. Rush CR (1998). Behavioral pharmacology of zolpidem relative to benzodiaze-pines: a review. Pharmacol Biochem Behav 61:253-269. (Pubitemid 28498208)
36. Rush CR, Griffiths RR (1996). Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 16:146-157. (Pubitemid 26141752)
37. Rush CR, Armstrong DL, Ali JA, Pazzaglia PJ (1998). Benzodiazepine- receptor ligands in humans: acute performance-impairing, subject-rated and observer-rated effects. J Clin Psychopharmacol 18:154-165.
38. Rush CR, Baker RW, Wright K (1999). Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology 144: 220-233. (Pubitemid 29307273)
39. Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, et al. (2002). Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol 451:103-110. (Pubitemid 35253948)
40. Schuckit MA, Tipp JE, Smith TL, Wiesbeck GA, Kalmijn J (1997). The relationship between Self-Rating of the Effects of alcohol and alcohol challenge results in ninety-eight young men. J Stud Alcohol 58:397-404. (Pubitemid 27264018)
41. Shames JL, Ring H (2008). Transient reversal of anoxic brain injury-related minimally conscious state after zolpidem administration: a case report. Arch Phys Med Rehabil 89:386-388.
42. Stoops WW, Rush CR (2003). Differential effects in humans after repeated administrations of zolpidem and triazolam. Am J Drug Alcohol Abuse 29:281-299. (Pubitemid 36578417)
43. Stoops WW, Lile JA, Fillmore MT, Glaser PE, Rush CR (2005). Reinforcing effects of methylpheniate: influence of dose and behavioral demands following drug administration. Psychopharmacology 177:349-355. (Pubitemid 40137296)
44. Svitek J, Heberlein A, Bleich S, Wiltfang J, Kornhuber J, Hillemacher T (2008). Extensive craving in high dose zolpidem dependency. Prog Neuropsycho-pharmacol Biol Psychiatry 32:591-592. (Pubitemid 351178980)
45. Westenberg HG (2009). Recent advances in understanding and treating social anxiety disorder. CNS Spectr 14:24-33.
46. Whyte J, Myers R (2009). Incidence of clinically significant responses to zolpidem among patients with disorders of consciousness: a preliminary placebo controlled trial. Am J Phys Med Rehabil 88:410-418.
47. Woods JH, Katz JL, Winger G (1992). Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 44:151-347.